TNFSF15 and primary biliary cholangitis: Serum TL1A levels are decreased in early-stage but not late-stage patients being treated with ursodeoxycholic acid, the only therapeutic drug for PBC approved by the Food and Drug Administration, suggesting that TL1A has a potential to be a new serum marker and therapeutic target for PBC [77].